The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy

Frontiers in Oncology

Dan Zang¹  Jun Chen¹  Min Zhang¹  Xiuhua Li¹  Dan Liu¹  Meixi Lin¹  Xu Han¹  Xiangjun Liu¹  Huan Zhou¹  Jinzhe Sun¹  Bing Gao²  Ye Cheng² 

[1] Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China;Department of Oncology, The Third Hospital of Dalian Medical University, Dalian, China;

关键词: gut microbiota;    lung cancer;    immunotherapy;    gut-lung axis;    biomarker;   

DOI  :  10.3389/fonc.2021.720842

来源: DOAJ

【 摘 要 】

The influence of microbiota on host health and disease has attracted adequate attention, and gut microbiota components and microbiota-derived metabolites affect host immune homeostasis locally and systematically. Some studies have found that gut dysbiosis, disturbance of the structure and function of the gut microbiome, disrupts pulmonary immune homeostasis, thus leading to increased disease susceptibility; the gut-lung axis is the primary cross-talk for this communication. Gut dysbiosis is involved in carcinogenesis and the progression of lung cancer through genotoxicity, systemic inflammation, and defective immunosurveillance. In addition, the gut microbiome harbors the potential to be a novel biomarker for predicting sensitivity and adverse reactions to immunotherapy in patients with lung cancer. Probiotics and fecal microbiota transplantation (FMT) can enhance the efficacy and depress the toxicity of immune checkpoint inhibitors by regulating the gut microbiota. Although current studies have found that gut microbiota closely participates in the development and immunotherapy of lung cancer, the mechanisms require further investigation. Therefore, this review aims to discuss the underlying mechanisms of gut microbiota influencing carcinogenesis and immunotherapy in lung cancer and to provide new strategies for governing gut microbiota to enhance the prevention and treatment of lung cancer.

【 授权许可】

Unknown